Wall Street brokerages expect TAIWAN LIPOSOME/S (NASDAQ:TLC) to report sales of $3.00 million for the current quarter, Zacks reports. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings, with estimates ranging from $400,000.00 to $5.59 million. TAIWAN LIPOSOME/S reported sales of $480,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 525%. The firm is scheduled to announce its next quarterly earnings report on Friday, May 10th.
According to Zacks, analysts expect that TAIWAN LIPOSOME/S will report full year sales of $4.97 million for the current year, with estimates ranging from $1.60 million to $8.33 million. For the next year, analysts anticipate that the business will report sales of $2.11 million, with estimates ranging from $1.60 million to $2.61 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover TAIWAN LIPOSOME/S.
TAIWAN LIPOSOME/S (NASDAQ:TLC) last posted its earnings results on Monday, April 1st. The company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.47 million. TAIWAN LIPOSOME/S had a negative return on equity of 167.30% and a negative net margin of 1,442.64%.
Several research firms have issued reports on TLC. Cantor Fitzgerald set a $11.00 target price on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a research report on Friday, April 5th. HC Wainwright reaffirmed a “buy” rating on shares of TAIWAN LIPOSOME/S in a research note on Thursday, April 18th. Finally, Zacks Investment Research raised TAIWAN LIPOSOME/S from a “sell” rating to a “hold” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.33.
A hedge fund recently bought a new stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC purchased a new position in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned 0.34% of TAIWAN LIPOSOME/S as of its most recent SEC filing. 2.17% of the stock is owned by institutional investors.
TLC stock remained flat at $$6.00 during trading on Friday. The company had a trading volume of 200 shares, compared to its average volume of 2,406. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.45 and a quick ratio of 3.19. TAIWAN LIPOSOME/S has a 1 year low of $5.02 and a 1 year high of $11.00. The firm has a market cap of $185.58 million and a PE ratio of -12.77.
About TAIWAN LIPOSOME/S
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Featured Story: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.